14 Nov ‘Unprecedented’ pace of COVID-19 drug development pushing Madison companies to expand
Spurred on by the push to end the COVID-19 pandemic, Catalent Biologics is rapidly expanding its Madison facilities and staff to account for increased production of substances used by various pharmaceutical companies around the world.
Catalent manufactures the drug substances — or active ingredients — which are used to make the final drug given to patients. Now, the company is working to combat COVID-19 by working with pharmaceutical companies developing treatments and vaccines.
In response to the uptick in production needs, Catalent accelerated its existing plans to open the new facilities. The 60,000-square-foot manufacturing expansion to the facility is now on schedule to open halfway through next year.
Catalent is far from the only business in Madison fighting to end the pandemic.